OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer

Background OX40 is a TNF receptor family member expressed by activated T cells. Its triggering by OX40 ligand promotes lymphocyte survival and memory generation. Anti-OX40 agonistic monoclonal antibodies (mAb) are currently being tested in cancer immunotherapy. We explored the prognostic significance of tumor infiltration by OX40+ cells in a large colorectal cancer (CRC) collective. Methods OX40 gene expression was analyzed in 50 freshly excised CRC and corresponding healthy mucosa by qRT-PCR. A tissue microarray including 657 clinically annotated CRC specimens was stained with anti-OX40, -CD8 and -FOXP3 mAbs by standard immunohistochemistry. The CRC cohort was randomly split into training and validation sets. Correlations between CRC infiltration by OX40+ cells alone, or in combination with CD8+ or FOXP3+ cells, and clinical-pathological data and overall survival were comparatively evaluated. Results OX40 gene expression in CRC significantly correlated with FOXP3 and CD8 gene expression. High CRC infiltration by OX40+ cells was significantly associated with favorable prognosis in training and validation sets in univariate, but not multivariate, Cox regression analysis. CRC with OX40high/CD8high infiltration were characterized by significantly prolonged overall survival, as compared to tumors with OX40low/CD8high, OX40high/CD8low or OX40low/CD8low infiltration in both uni- and multivariate analysis. In contrast, prognostic significance of OX40+ and FOXP3+ cell infiltration was not enhanced by a combined evaluation. Irrespective of TNM stage, CRC with OX40high/CD8high density infiltrates showed an overall survival similar to that of all stage I CRC included in the study. Conclusions OX40high/CD8high density tumor infiltration represents an independent, favorable, prognostic marker in CRC with an overall survival similar to stage I cancers.

[1]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[2]  M. Koch,et al.  Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis. , 2015, The Journal of clinical investigation.

[3]  G. Antonelli,et al.  Human OX40 tunes the function of regulatory T cells in tumor and nontumor areas of hepatitis C virus–infected liver tissue , 2014, Hepatology.

[4]  L. Terracciano,et al.  GM-CSF Production by Tumor Cells Is Associated with Improved Survival in Colorectal Cancer , 2014, Clinical Cancer Research.

[5]  Jean-François Dartigues,et al.  Estimating and comparing time‐dependent areas under receiver operating characteristic curves for censored event times with competing risks , 2013, Statistics in medicine.

[6]  B. Fox,et al.  OX40 is a potent immune-stimulating target in late-stage cancer patients. , 2013, Cancer research.

[7]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[8]  N. Morris,et al.  Science gone translational: the OX40 agonist story , 2011, Immunological reviews.

[9]  L. Terracciano,et al.  Tumor infiltration by FcγRIII (CD16)+ myeloid cells is associated with improved survival in patients with colorectal carcinoma , 2011, International journal of cancer.

[10]  J. Galon,et al.  Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. , 2011, Cancer research.

[11]  L. Terracciano,et al.  TIA-1 Cytotoxic Granule-Associated RNA Binding Protein Improves the Prognostic Performance of CD8 in Mismatch Repair-Proficient Colorectal Cancer , 2010, PloS one.

[12]  T. Beißbarth,et al.  Mutated KRAS results in overexpression of DUSP4, a MAP‐kinase phosphatase, and SMYD3, a histone methyltransferase, in rectal carcinomas , 2010, Genes, chromosomes & cancer.

[13]  Krzysztof Goryca,et al.  Modeling Oncogenic Signaling in Colon Tumors by Multidirectional Analyses of Microarray Data Directed for Maximization of Analytical Reliability , 2010, PloS one.

[14]  L. Terracciano,et al.  High frequency of tumor‐infiltrating FOXP3+ regulatory T cells predicts improved survival in mismatch repair‐proficient colorectal cancer patients , 2010, International journal of cancer.

[15]  M. Croft.  Control of immunity by the TNFR-related molecule OX40 (CD134). , 2010, Annual review of immunology.

[16]  Thomas Downey,et al.  A ‘metastasis-prone’ signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics , 2010, Clinical & Experimental Metastasis.

[17]  Maria T. Abreu,et al.  Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function , 2010, Nature Reviews Immunology.

[18]  L. Terracciano,et al.  CD8+ lymphocytes/ tumour-budding index: an independent prognostic factor representing a ‘pro-/anti-tumour’ approach to tumour host interaction in colorectal cancer , 2009, British Journal of Cancer.

[19]  N. Zeps,et al.  Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Weinberg,et al.  OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. , 2008, Cancer research.

[21]  I. Zlobec,et al.  Prognostic and predictive factors in colorectal cancer , 2008, Journal of Clinical Pathology.

[22]  S. Rha,et al.  Whole genome analysis for liver metastasis gene signatures in colorectal cancer , 2007, International journal of cancer.

[23]  T. Yeatman,et al.  Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer , 2007, Genome Biology.

[24]  T. Curiel,et al.  Tregs and rethinking cancer immunotherapy. , 2007, The Journal of clinical investigation.

[25]  R. Steele,et al.  Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer , 2006, Journal of Clinical Pathology.

[26]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[27]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[28]  Z. Trajanoski,et al.  Effector memory T cells, early metastasis, and survival in colorectal cancer. , 2005, The New England journal of medicine.

[29]  Eero Pukkala,et al.  Cancer risk in hereditary nonpolyposis colorectal cancer syndrome: later age of onset. , 2005, Gastroenterology.

[30]  A. Weinberg,et al.  The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement , 2004, Journal of leukocyte biology.

[31]  K. Sugamura,et al.  Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40 , 2004, Nature Reviews Immunology.

[32]  M. Croft,et al.  Costimulation of CD8 T Cell Responses by OX401 , 2004, The Journal of Immunology.

[33]  M. Glennie,et al.  Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4‐1BB), and their role in the generation of anti‐tumor immune responses , 2002, European journal of immunology.

[34]  C. Corless,et al.  Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134). , 2002, American journal of surgery.

[35]  C. Maliszewski,et al.  Ox40 Costimulation Enhances the Development of T Cell Responses Induced by Dendritic Cells In Vivo , 2002, The Journal of Immunology.

[36]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[37]  G. Alvord,et al.  Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity1 , 2000, The Journal of Immunology.

[38]  A. Weinberg,et al.  Danger and OX40 Receptor Signaling Synergize to Enhance Memory T Cell Survival by Inhibiting Peripheral Deletion1 , 2000, The Journal of Immunology.

[39]  J. Cuzick,et al.  The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases , 1986, Histopathology.

[40]  A. Weinberg,et al.  OX40 (CD134) and OX40L. , 2009, Advances in experimental medicine and biology.

[41]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.

[42]  J. Hardcastle,et al.  Colorectal cancer , 1993, Europe Against Cancer European Commission Series for General Practitioners.